Second, a recent study demonstrated evidence that NSD2 overexpression in multiple myeloma opens the chromatin through deposition of H3K36me2, which allows binding of transcription factors such as AP-1, to recruit CBP/p300, thereby mediating the deposition of H3K27ac, a well-defined marker of enhancer activity [44]. The gene discussed is EP300; the disease is plasma cell myeloma.